Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine and Capecitabine for Luminal B Breast Cancer After Neoadjuvant Chemotherapy
NCT04307147Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Jul 2018
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine and capecitabine in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04307147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307147.